Colistin

CHEMBL6067481 Phase 4 Approuvé Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1155.4 g/mol

LogP

-3.3

Phase

4

A polymyxin antibiotic that disrupts the outer membrane of Gram-negative bacteria, used as a last-resort treatment for infections caused by multidrug-resistant organisms such as Acinetobacter and Pseudomonas. Its significant risk of kidney and nerve toxicity limits its use to severe infections with no other options.

Masse moléculaire

1155,4000 g/mol

LogP

-3,30

TPSA

491,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Infectious Disease Systemic Lupus Erythematosus Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@@H](C)O

InChI

InChI=1S/C52H98N16O13/c1-9-29(6)11-10-12-40(71)59-32(13-19-53)47(76)68-42(31(8)70)52(81)64-35(16-22-56)44(73)63-37-18-24-58-51(80)41(30(7)69)67-48(77)36(17-23-57)61-43(72)33(14-20-54)62-49(78)38(25-27(2)3)66-50(79)39(26-28(4)5)65-45(74)34(15-21-55)60-46(37)75/h27-39,41-42,69-70H,9-26,53-57H2,1-8H3,(H,58,80)(H,59,71)(H,60,75)(H,61,72)(H,62,78)(H,63,73)(H,64,81)(H,65,74)(H,66,79)(H,67,77)(H,68,76)/t29?,30-,31-,32+,33+,34+,35+,36+,37+,38+,39-,41+,42+/m1/s1

Molecular Formula

C52H98N16O13

HBD / HBA

18 / 18

Liaisons Rotatives

28

Atomes Lourds

81

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A polymyxin antibiotic that disrupts the outer membrane of Gram-negative bacteria, used as a last-resort treatment for infections caused by multidrug-resistant organisms such as Acinetobacter and Pseudomonas. Its significant risk of kidney and nerve toxicity limits its use to severe infections with no other options.

Yes, Colistin is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6067481. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5311054. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Colistin sur PillFYI

Structure

Données Clés

Formule: C52H98N16O13
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.